CRISPR: Technology that powers Cancer treatment

Cancer is a condition when a few of the body's cells grow out of control. Tumors, which are tissue masses, can develop from these cells. The mutations in DNA are the root cause of cancer. Scientists have been looking for a simple technique to reverse these alterations by modifying DNA. Although many gene editing techniques have been created over the years, none have matched the criteria for a rapid, simple, and affordable technology. But in 2013, numerous studies revealed that a gene-editing tool known as CRISPR could modify the DNA of human cells like that of an extremely accurate and user-friendly pair of scissors. Although CRISPR research is still in its early stages, preliminary laboratory results have already been encouraging.

In 2016, the first patient in the world to get CRISPR treatment was a lung cancer patient. In a clinical experiment in China, this patient received an injection of PD-1 modified T cells. This study's major objectives were to determine whether the therapy was secure, whether any adverse effects were manageable, and whether it triggered a harmful immune response. Fever, rash, and weariness were tolerable side effects of the medication, which was safe to give. Before being infused into the patient, a median of 6% of T cells contained the intended modification in each patient. At modest levels, edited T cells were discovered in 11 out of 12 individuals two months following the injection. Patients with greater edited cell levels experienced less illness.
In 2019, a CRISPR-made cancer therapy was launched at the University of Pennsylvania. The study tests a type of immunotherapy in which patient's immune cells are genetically modified to better "see" and kill their cancer. A trial of CRISPR-edited cell therapy has shown that the treatment is safe and effective. It was tested in three patients with various types of cancer and had a small effect on their tumors. Some side effects did occur, but they were likely caused by chemotherapy patients receiving before the infusion of modified cells. This experiment] was a proof-of-concept, practicality, and safety measure that now open up the entire field of CRISPR and other gene editing methods in the hopes of developing the generation of medicines.
The Center for RNA Biology at the University of Rochester has discovered a novel strategy that may be used to inhibit the rapidly proliferating cells that are a hallmark of all cancers. The researcher isolated a protein, Tudor-SN, which aids in getting a cell ready to divide, and the researchers cut it out using CRISPR-Cas9. Since cancer cells exhibit a deficiency in cell division, cutting out this protein may enable to cure or inhibit the spread of the disease. The results were made in vitro in kidney and cervical cancer cells, and human application is still far away. However, the scientists speculated that they might one day serve as the foundation for a therapy alternative.
In August 2022, Researchers from the Imperial College London and Charité - Universitätsmedizin Berlin revealed that the signal for CRISPR-based diagnostics has now been improved by employing a cutting-edge technique called CrisprZyme. The test may also be used at room temperature and is simple. The outcome is visible with the unaided eye or with a paper strip. This simple test may enable future medical experts to distinguish between certain types of prostate cancer and identify biomarkers for sudden heart attacks.